SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 ...
The biotech—which went public earlier this year via a merger with Homology Medicines—had been evaluating bempikibart in a phase 2b study of 106 patients with moderate to severe atopic dermatitis.
SIGNAL-AD is a Phase 2a clinical trial evaluating lead drug candidate Bempikibart in adult patients with persistent, moderate-to-severe atopic dermatitis, comprising of two parts - Part A and Part B.
SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback